Michael Chuong, Vice Chair and Medical Director of the Department of Radiation Oncology at Miami Cancer Institute, GI Section Editor at International Journal Radiation Oncology, Biology, Physics and Professor at FIU Herbert Wertheim College of Medicine, shared a post on LinkedIn:
“Thanks to European Society for Radiotherapy and Oncology (ESTRO) for the opportunity this past weekend to present the initial results of our phase 1 trial of ablative 5-fraction reirradiation for abdominal and pelvic tumors at ESTRO 2026.
Very promising outcomes despite median prior dose of 50 Gy in a median 5 fractions.
We observed no grade 3 or higher toxicity, 1-year LC 100%.
More presentations from this trial are planning including a dosimetric analysis of cumulative dose that will be presented at ASTRO 2026 by Kathryn Mittauer so stay tuned!”
Other articles featuring Michael Chuong on OncoDaily.